Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-cash Items (2019 - 2024)

Capricor Therapeutics has reported Non-cash Items over the past 7 years, most recently at $101.8 million for Q4 2024.

  • Quarterly results put Non-cash Items at $101.8 million for Q4 2024, up 653.98% from a year ago — trailing twelve months through Dec 2024 was $101.8 million (up 653.98% YoY), and the annual figure for FY2024 was $101.8 million, up 653.98%.
  • Non-cash Items for Q4 2024 was $101.8 million at Capricor Therapeutics, up from $6.1 million in the prior quarter.
  • Over the last five years, Non-cash Items for CAPR hit a ceiling of $101.8 million in Q4 2024 and a floor of $171000.0 in Q1 2020.
  • Median Non-cash Items over the past 5 years was $5.3 million (2024), compared with a mean of $11.1 million.
  • Biggest five-year swings in Non-cash Items: soared 4812.28% in 2021 and later plummeted 72.99% in 2023.
  • Capricor Therapeutics' Non-cash Items stood at $4.2 million in 2020, then decreased by 26.72% to $3.1 million in 2021, then surged by 225.32% to $10.1 million in 2022, then skyrocketed by 33.66% to $13.5 million in 2023, then soared by 653.98% to $101.8 million in 2024.
  • The last three reported values for Non-cash Items were $101.8 million (Q4 2024), $6.1 million (Q3 2024), and $5.5 million (Q2 2024) per Business Quant data.